🇺🇸 FDA
Pipeline program

cemiplimab

R1979-ONC-1504

Phase 1 small_molecule active

Quick answer

cemiplimab for Relapsed/Refractory Aggressive B-Cell Lymphoma is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Relapsed/Refractory Aggressive B-Cell Lymphoma
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials